{"id":3155,"date":"2016-01-06T17:34:01","date_gmt":"2016-01-06T17:34:01","guid":{"rendered":"http:\/\/www.medicalmarijuanainc.com\/?p=5220"},"modified":"2016-01-06T17:34:01","modified_gmt":"2016-01-06T17:34:01","slug":"medical-marijuana-inc-portfolio-company-axim-biotech-featured-by-reuters-for-patented-cannabinoid-chewing-gum","status":"publish","type":"post","link":"https:\/\/medicalmarijuanainc.com\/2016\/01\/06\/medical-marijuana-inc-portfolio-company-axim-biotech-featured-by-reuters-for-patented-cannabinoid-chewing-gum\/","title":{"rendered":"Medical Marijuana Inc. Portfolio Company AXIM Biotech Featured By Reuters For Patented Cannabinoid Chewing Gum"},"content":{"rendered":"
AXIM\u00ae Biotech\u2019s Clinical Trials on MedChew Rx\u2122 Patented Cannabinoid Release Chewing Gum Provides New Medicine Delivery Method for Healthcare Industry<\/em><\/p>\n SAN DIEGO, CA – January 6, 2016<\/strong> \u2013 Medical Marijuana, Inc.<\/a> (OTC Pink: MJNA) is proud to announce to the public and its shareholders that its portfolio investment<\/a>, AXIM\u00ae Biotechnologies, Inc. (OTC: AXIM), was recently featured in a Health article by Reuters<\/a> global news agency. The article profiles AXIM\u2019s role in developing the world\u2019s first patented cannabinoid release chewing gum<\/a> (i.e.THC, CBD, CBG, etc.) \u2013 MedChew Rx\u2122 \u2013 for pain and spasticity in multiple sclerosis (MS)<\/a>.<\/p>\n \u201cAXIM\u00ae is not \u2018chewing into\u2019 the existing global pharmaceutical market; it is opening a new medical delivery method with the world\u2019s first patented cannabis-based, controlled-release chewing gum,\u201d states Dr. Stuart W. Titus, Chief Executive Officer of Medical Marijuana, Inc. \u201cOur hats go off to AXIM\u2019s executive leadership. This innovative biotech is clearly on the fast track to becoming a major contributor to the life sciences industry.\u201d<\/p>\n Worldwide estimates are approximately 2.5 million individuals diagnosed with MS. Reuters explains that, \u201cThere is no cure for multiple sclerosis, or MS, which affects about 400,000 people in the United States. About 80 percent of patients suffer from spasticity\u2026\u201d<\/p>\n Reuters also states that GW Pharmaceuticals\u2019 Sativex\u2122 costs on average 5.56 pounds ($8.24 USD per dose) with an estimate of four doses per day. In direct comparison, at $32.96 per day or just over $12,000 per year – assuming that all MS patients suffer from pain, the U.S. market potential for MedChew Rx\u2122 can then be estimated at $4.8 billion annually.<\/p>\n The global pharmaceutical market is reported to be worth nearly $1.6 trillion by 2020. AXIM\u00ae Biotech intends to develop innovative pharmaceutical delivery systems and API (active pharmaceutical ingredients) for treatment of conditions such as: MS, spasticity, pain, Parkinson\u2019s disease<\/a>, Alzheimer\u2019s disease\/dementia<\/a>, ADHD (attention deficit hyperactivity disorder), psychosis, PTSD<\/a>, autism<\/a>, RLS (restless leg syndrome), glaucoma<\/a>, IBD, IBS<\/a>, and Crohn\u2019s disease. All of these efforts are based on proprietary IP.<\/p>\n AXIM\u00ae Biotech is a significant investment company for Medical Marijuana, Inc<\/a>., which holds\u00a014,943,650 shares of common stock and 500,000 shares of preferred stock representing 45.5%\u00a0equity interest in the cutting-edge biotechnology innovator.<\/p>\n About Medical Marijuana Inc.<\/strong><\/em><\/p>\n The mission of Medical Marijuana, Inc. (OTC Pink: MJNA) is to be the premier cannabis and hemp industry innovator, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing\u00a0shareholder value. For more information on Medical Marijuana, Inc., please visit the company’s website at:\u00a0www.medicalmarijuanainc.com<\/a>.<\/p>\n About AXIM Biotechnologies:<\/strong><\/p>\n AXIM Biotechnologies (OTC: AXIM) is an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products where we prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, visit the Company website at: www.AXIMBiotech.com<\/a>.<\/p>\n FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE<\/em><\/p>\n These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.<\/p>\n FORWARD-LOOKING DISCLAIMER<\/em><\/p>\n This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and\/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause\u00a0the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.<\/p>\n LEGAL DISCLOSURE<\/p>\n Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). Their companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based\u00a0Cannabidiol is a natural constituent of hemp oil. For further information, please contact:<\/p>\n Public Relations contact: Corporate contact: MEDICAL MARIJUANA, INC. INVESTMENT \u2013 AXIM BIOTECH \u2013 FEATURED BY\u00a0REUTERS; CANNABIS \u201cGUM TO TREAT MULTIPLE SCLEROSIS\u201d PAIN AND\u00a0SPASTICITY AXIM\u00ae Biotech\u2019s Clinical Trials on MedChew Rx\u2122 Patented Cannabinoid Release Chewing Gum Provides New Medicine Delivery Method for Healthcare Industry SAN DIEGO, CA – January 6, 2016 \u2013 Medical Marijuana, Inc. (OTC Pink: MJNA) is proud to […]<\/p>\n","protected":false},"author":1,"featured_media":3156,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[160,3,2],"tags":[183,49],"class_list":["post-3155","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-axim-biotechnologies","category-company-news","category-press-releases","tag-axim-biotechnologies","tag-medical-marijuana-inc"],"yoast_head":"\n
\nAndrew Hard
\nChief Executive Officer
\nCMW Media
\nP. 888-829-0070
\nandrew.hard@cmwmedia.com
\nwww.cmwmedia.com<\/p>\n
\nMedical Marijuana, Inc.
\nToll Free: 888-OTC-MJNA (888-682-6562)
\nwww.medicalmarijuanainc.com
\nwww.facebook.com\/mjnainc \t<\/p>\n","protected":false},"excerpt":{"rendered":"